Key result
A 6-month nutrition intervention of dietary sodium reduction, lycopene, and omega-3 fatty acids will be evaluated against placebo in 175 patients with advanced heart failure.
Why the study?
Does a 6-month nutrition intervention of dietary sodium reduction, lycopene, and omega-3 fatty acids improve symptom burden, health-related quality of life, and time to heart failure rehospitalization or all-cause death in patients with advanced heart failure?
RCT (n=175)
Double-blind
randomized
Does a 6-month nutrition intervention of dietary sodium reduction, lycopene, and omega-3 fatty acids improve symptom burden, health-related quality of life, and time to heart failure rehospitalization or all-cause death in patients with advanced heart failure?
Answers are grounded in this paper and cite their sources.
For a majority of patients with advanced heart failure, there is a need for complementary, non-pharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this double blind-placebo controlled study are (1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health-related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; (2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and (3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 175 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group.
No takes yet. Share an insight, caveat, or question.
Lennie et al. (2013) conducted an RCT in advanced heart failure (n=175). dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids vs. placebo was evaluated on symptom burden (edema, shortness of air, and fatigue), health-related quality of life, and time to heart failure rehospitalization or all-cause death. A 6-month nutrition intervention of dietary sodium reduction, lycopene, and omega-3 fatty acids will be evaluated against placebo in 175 patients with advanced heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: